Your browser is no longer supported. Please, upgrade your browser.
OREX [NASD]
Orexigen Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.34 Insider Own0.10% Shs Outstand123.46M Perf Week45.13%
Market Cap1.05B Forward P/E- EPS next Y-0.25 Insider Trans-72.20% Shs Float122.20M Perf Month66.47%
Income-37.50M PEG- EPS next Q-0.17 Inst Own92.50% Short Float31.33% Perf Quarter46.63%
Sales55.50M P/S18.89 EPS this Y37.00% Inst Trans2.82% Short Ratio8.57 Perf Half Y48.43%
Book/sh0.14 P/B60.64 EPS next Y47.20% ROA-37.60% Target Price10.71 Perf Year17.92%
Cash/sh0.96 P/C8.83 EPS next 5Y20.00% ROE-297.30% 52W Range3.11 - 9.37 Perf YTD40.10%
Dividend- P/FCF- EPS past 5Y21.90% ROI-63.30% 52W High-11.26% Beta2.47
Dividend %- Quick Ratio7.00 Sales past 5Y102.40% Gross Margin- 52W Low167.37% ATR0.58
Employees50 Current Ratio7.10 Sales Q/Q2577.90% Oper. Margin-55.00% RSI (14)78.79 Volatility17.61% 7.98%
OptionableYes Debt/Eq4.91 EPS Q/Q147.40% Profit Margin- Rel Volume5.24 Prev Close8.49
ShortableYes LT Debt/Eq4.91 EarningsFeb 25 BMO Payout- Avg Volume4.47M Price8.32
Recom1.60 SMA2042.03% SMA5044.62% SMA20053.07% Volume5,223,097 Change-2.06%
Jan-23-15Initiated RBC Capital Mkts Outperform $10
Jan-10-14Initiated WallachBeth Buy $9
Oct-03-13Initiated Cowen Outperform $10
Sep-21-11Upgrade JMP Securities Mkt Perform → Mkt Outperform $5
Feb-01-11Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-01-11Downgrade Canaccord Genuity Buy → Hold
Dec-03-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform
Jul-16-10Reiterated JMP Securities Mkt Outperform $16 → $13
Jul-16-10Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Feb-02-10Initiated Jefferies & Co Buy $12
Jun-24-09Initiated Rodman & Renshaw Mkt Outperform $14
Mar-13-09Reiterated Lazard Capital Mkts Buy $13 → $10
Apr-03-08Initiated Cowen & Co Outperform
Feb-06-08Initiated Lazard Capital Buy
Feb-04-08Reiterated Canaccord Adams Buy $29 → $32
Jan-03-08Initiated JP Morgan Overweight
Oct-03-07Upgrade JMP Securities Mkt Outperform → Strong Buy $26
Jun-07-07Initiated JP Morgan Overweight
Jun-06-07Initiated JMP Securities Mkt Outperform $26
Mar-05-15 09:30AM  The Zacks Analyst Blog Highlights: Amgen, Gilead, Celgene and Orexigen - Press Releases Zacks
Mar-04-15 06:18PM  Nasdaq stocks posting largest volume increases AP +11.13%
06:18PM  Nasdaq stocks posting largest percentage increases AP
05:30PM  Orexigen soars on drug data CNBC
04:45PM  Orexigen Soars as Interim Data on Contrave Comes to Light - Analyst Blog Zacks
03:05PM  Orexigen Therapeutics (OREX) Stock Surging Today on Heavy Volume at TheStreet
01:28PM  Wednesday's Mid-Day Movers: PhotoMedex, Career Education And More Benzinga
11:35AM  Biotech Stock Roundup: Orexigen Soars on Contrave Data, Amgen Scores in Study - Analyst Blog Zacks
10:57AM  Fat Chance: FDA Chastises Orexigen for Disclosing Interim Trial Data at The Wall Street Journal
Mar-03-15 09:07PM  Report: Orexigen Therapeutics Jumped Gun On Contrave Heart Study Benzinga +31.95%
04:44PM  Orexigen Jumps on Diet Pills Heart Benefit as FDA Frowns at Bloomberg
04:44PM  Best Buy and Orexigen are big market movers AP
04:13PM  Orexigen Comments On Data Disclosure That "Disappointed" FDA at Forbes
03:36PM  Nasdaq backs off from 5,000 CNBC
03:33PM  The FDA Is Forcing Orexigen To Do A Second Safety Study Because Of Contrave Disclosures at Forbes
02:16PM  Has Orexigen Endangered Its Future To Boost Its Stock? at Forbes
02:06PM  Orexigen Released Interim Data Without Approval Of Trial Leaders at Forbes
01:54PM  Orexigen Soars On Obesity Drug's Surprise Health Boon at Investor's Business Daily
11:51AM  Orexigen Weight-Loss Pill Shows Surprise Heart-Safety Benefit at TheStreet
Mar-02-15 06:05PM  What Are The Real Economic Costs Of Obesity? at Investopedia
Feb-27-15 03:08PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 10-K, Annual Report EDGAR Online
Feb-26-15 09:30AM  Orexigen (OREX) Misses Q4 Earnings, Contrave Impresses - Analyst Blog Zacks
Feb-25-15 07:30AM  Orexigen Therapeutics Inc Earnings Call scheduled for 7:30 am ET today CCBN
07:07AM  Q4 2014 Orexigen Therapeutics Inc Earnings Release - Before Market Open CCBN
06:45AM  Orexigen misses 4Q profit forecasts AP
06:42AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
06:30AM  Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2014 PR Newswire
Feb-23-15 08:30AM  Orexigen Therapeutics to Speak at the 2015 RBC Capital Markets Global Healthcare Conference PR Newswire
Feb-20-15 04:45PM  Orexigen Therapeutics to Host Full Year and Fourth Quarter 2014 Financial Results Conference Call and Webcast PR Newswire
03:47PM  Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus at TheStreet
Feb-10-15 04:30PM  Orexigen Gives Positive Updates on its Weight Loss Drug - Analyst Blog Zacks
Feb-09-15 08:06AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events EDGAR Online
08:00AM  Orexigen Provides Progress Update on Mysimba European Marketing Authorization PR Newswire
Feb-06-15 04:15PM  Orexigen Therapeutics to Speak at the Leerink Global Healthcare Conference PR Newswire
Feb-05-15 04:53PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Jan-28-15 03:13PM  Consumer Groups Urge Europe not to Approve the Orexigen Diet Pill at The Wall Street Journal
Jan-23-15 06:20AM  Coverage initiated on Orexigen Therapeutics by RBC Capital Mkts Briefing.com
Jan-16-15 07:00AM  Orexigen Therapeutics, Inc. (OREX): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Zacks +5.62%
Jan-14-15 01:55PM  5 Obesity Stocks Investors Are Watching Benzinga
Jan-13-15 02:22PM  Orexigen CEO: Excited about obesity drug progress CNBC -5.57%
Jan-12-15 06:16AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Jan-08-15 09:00AM  Orexigen Therapeutics to Present at the J.P. Morgan 2015 Healthcare Conference PR Newswire
Dec-29-14 09:39AM  Novo Nordisk to promote drug to treat obesity in United States Reuters
Dec-23-14 04:49PM  FDA clears Novo Nordisk's weight loss drug Saxenda AP
Dec-19-14 04:24PM  New highs! The S&P 500 closes just below its prior record close... Yahoo Finance Contributors
03:22PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events EDGAR Online
02:09PM  Orexigen Therapeutics Gains On Diet Pill Nod From European Committee Benzinga
08:25AM  Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators at TheStreet
07:37AM  European regulators recommend approval of Orexigen's obesity pill Reuters
07:19AM  Orexigen's Mysimba (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP Opinion Recommending Approval for Weight Management in the European Union PR Newswire
Dec-18-14 01:44PM  Six Biotech and Technology Stocks With Strong Technical Set-Ups at TheStreet
Dec-17-14 07:42AM  Bio-Twitter Sentiment Favors European Orexigen Obesity Pill Approval Yahoo Finance Blogs +7.77%
Dec-12-14 11:58AM  Obesity Pill Upstart Orexigen Therapeutics Gaining on Rivals Yahoo Finance Blogs
Dec-08-14 03:31PM  These 4 Biotech Stocks Have Been On Fire Benzinga
Dec-05-14 05:50AM  Why Orexigen Therapeutics (OREX) Stock Might be a Great Pick Zacks
Dec-03-14 05:51AM  Earnings Estimates Moving Higher for Orexigen (OREX): Time to Buy? Zacks
Nov-26-14 08:30AM  Orexigen Therapeutics to Present at the Piper Jaffray Healthcare Conference PR Newswire
Nov-21-14 08:00AM  Orexigen Announces Allowance of New U.S. Patent for Contrave® (naltrexone HCl / bupropion HCl extended release) PR Newswire
Nov-19-14 01:50PM  Is Orexigen Really Worth Over 50% More? at 24/7 Wall St.
Nov-18-14 01:04PM  OREXIGEN THERAPEUTICS, INC. Financials EDGAR Online Financials
Nov-17-14 11:33AM  2 Skyrocketing Biotech Stocks In A Stalling Market Benzinga
Nov-14-14 06:00AM  Biotech Stock Mailbag: Spectrum, Intercept, Orexigen, Amarin, MannKind at TheStreet
Nov-13-14 12:10PM  What's Driving Orexigen Therapeutics Higher? Benzinga
Nov-12-14 07:09PM  10-Q for Orexigen Therapeutics, Inc. Company Spotlight +15.87%
04:42PM  A ho-hum day in the markets as stocks open weaker, but recover to close mixed... Yahoo Finance Blogs
01:02PM  Orexigen Therapeutics Continues To Rally at TheStreet
Nov-11-14 10:20AM  Orexigen Turns Around with Q3 Earnings Beat, Shares Soar Zacks
09:46AM  Today's Perilous Reversal Stock: Orexigen Therapeutics (OREX) at TheStreet
06:38AM  Orexigen (OREX) Worth Watching: Stock Soars 33.3% Zacks
Nov-10-14 02:53PM  Orexigen Therapeutics (OREX) Stock Continues to Rise as EU Reviews Contrave Drug at TheStreet +33.25%
11:02AM  Orexigen rises as weight loss drug review proceeds AP
10:33AM  Orexigen Therapeutics (OREX) Stock Soars Today on Big Third Quarter Earnings Beat at TheStreet
08:30AM  Orexigen Therapeutics Inc Earnings Call scheduled for 8:30 am ET today CCBN
07:18AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
07:07AM  Q3 2014 Orexigen Therapeutics Inc Earnings Release - Before Market Open CCBN
07:00AM  Orexigen Therapeutics Reports Results for the Third Quarter Ended September 30, 2014 PR Newswire
Nov-06-14 04:30PM  Orexigen Therapeutics to Present at the Credit Suisse Healthcare Conference PR Newswire
Nov-04-14 04:15PM  Orexigen Therapeutics to Host Third Quarter 2014 Financial Results Conference Call and Webcast PR Newswire
Oct-31-14 08:30AM  Orexigen Announces Contrave® (naltrexone HCI and bupropion HCI extended release) Data Presentations at the ObesityWeek Meeting in Boston PR Newswire
Oct-22-14 07:32AM  Orexigen (OREX) Shows Strength: Stock Gains 11.1% Zacks
Oct-20-14 08:00AM  Takeda and Orexigen Announce Availability of CONTRAVE® (naltrexone HCI and bupropion HCI) Extended-Release Tablets for Chronic Weight Management in Obese Adults PR Newswire
Oct-16-14 01:25PM  Orexigen Up on $100M Milestone Payment from Takeda Zacks +5.28%
Oct-15-14 04:27PM  AbbVie and Bank of America are big market movers AP +15.03%
04:01PM  Shire PLC Takes A Dive As AbbVie Reconsiders Offer at TheStreet
08:30AM  Milestone Payments Earned by Orexigen Total $100 Million as Contrave® (naltrexone HCI and bupropion HCI extended release) is Shipped to Wholesalers in Preparation for Commercial Launch PR Newswire
Sep-18-14 08:25AM  The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead Zacks
Sep-17-14 02:00PM  Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved Zacks
Sep-16-14 04:15PM  Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference PR Newswire
10:30AM  Insider Trading Alert - HTGC, OREX And TEP Traded By Insiders at TheStreet
Sep-15-14 06:00AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online -5.43%
05:51AM  Selling Obesity Drugs to Americans Shouldn't Be This Hard at BusinessWeek
Sep-12-14 04:10PM  Novo Nordisk's Saxenda Gets Positive Opinion for Obesity Zacks
01:20PM  Nasdaq stocks posting largest percentage decreases AP
11:00AM  [video] Orexigen's anti-obesity pill wins FDA Approval at CNBC
Sep-11-14 05:23PM  FDA panel backs Novo Nordisk injection for obesity AP -10.51%
05:15PM  [video] Orexigen drops in spite of FDA approval at CNBC
04:10PM  How Will Orexigen Therapeutics (OREX) Stock Respond to FDA's Contrave Approval? at TheStreet
04:00PM  U.S. FDA panel: Novo Nordisk's liraglutide safe/effective for obesity Reuters
03:30PM  Orexigen's Obesity Drug Contrave Approved by the FDA Zacks
01:49PM  FDA approves weight-loss drug Contrave AP
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include NB32, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic that has completed Phase II clinical trials. Orexigen Therapeutics, Inc. has collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize NB32 in the United States, Canada, and Mexico. The company was founded in 2002 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Booth Mark DChief Commercial OfficerFeb 26Option Exercise1.6650,00083,00053,810Mar 02 05:34 PM
Booth Mark DChief Commercial OfficerFeb 26Sale5.6850,000284,2003,810Mar 02 05:34 PM
Turner Heather DSVP, Gen. Counsel & SecretaryDec 02Option Exercise1.6622,64337,58722,643Dec 04 05:05 PM
Turner Heather DSVP, Gen. Counsel & SecretaryDec 02Sale6.0022,643135,8580Dec 04 05:05 PM
Turner Heather DSVP, Gen. Counsel & SecretaryNov 25Option Exercise1.667,38212,2547,382Nov 26 05:01 PM
Turner Heather DSVP, Gen. Counsel & SecretaryNov 25Sale6.007,38244,2920Nov 26 05:01 PM
Turner Heather DSVP, Gen. Counsel & SecretaryNov 24Option Exercise1.6624,00639,85024,006Nov 26 05:01 PM
Turner Heather DSVP, Gen. Counsel & SecretaryNov 24Sale5.7724,006138,5870Nov 26 05:01 PM
BOCK LOUIS CDirectorNov 18Buy5.587003,905700Nov 20 09:16 AM
BOCK LOUIS CDirectorNov 18Buy5.586253,48727,677Nov 20 09:16 AM
BOCK LOUIS CDirectorNov 12Buy5.5727,052150,54427,052Nov 13 09:27 AM
Turner Heather DVP, Gen. Counsel & SecretarySep 22Option Exercise1.66300,000498,000300,000Sep 22 06:49 PM
Turner Heather DVP, Gen. Counsel & SecretarySep 22Sale4.47300,0001,339,5000Sep 22 06:49 PM
Hagan Joseph PSr. VP, Corporate DevelopmentSep 15Buy4.695,00023,45013,026Sep 15 03:11 PM
NARACHI MICHAELPresident and CEOSep 15Buy4.7850,000239,10058,026Sep 15 02:41 PM
DOVEY BRIAN HDirectorApr 22Option Exercise0.004,691,4704,6917,580,065Apr 23 05:15 PM